Figure 7.
Figure 7. The effect of atorvastatin on chemokine-release from HUVECs. HUVECs were preincubated (for 20 minutes) with ortho-hydroxy atorvastatin (AT; 10 μM) with and without mevalonate (MEV; 100 μM) before stimulation with rhLIGHT (100 ng/mL) for 5 hours. Atorvastatin reduced the rhLIGHT-mediated release of MCP-1 (A) and IL-8 (B). Data are presented as mean ± SEM, n = 6. *P < .05 versus stimulated HUVECs with solvent added instead of atorvastatin. #P < .05 shown for stimulated HUVECs preincubated with mevalonate and atorvastatin versus stimulated HUVECs preincubated with atorvastatin only.

The effect of atorvastatin on chemokine-release from HUVECs. HUVECs were preincubated (for 20 minutes) with ortho-hydroxy atorvastatin (AT; 10 μM) with and without mevalonate (MEV; 100 μM) before stimulation with rhLIGHT (100 ng/mL) for 5 hours. Atorvastatin reduced the rhLIGHT-mediated release of MCP-1 (A) and IL-8 (B). Data are presented as mean ± SEM, n = 6. *P < .05 versus stimulated HUVECs with solvent added instead of atorvastatin. #P < .05 shown for stimulated HUVECs preincubated with mevalonate and atorvastatin versus stimulated HUVECs preincubated with atorvastatin only.

Close Modal

or Create an Account

Close Modal
Close Modal